Sepracor, Inc. Release: LUNESTA(TM) Data Presented At American College Of Rheumatology Annual Scientific Meeting; Pilot Study Shows Improvement For Insomnia Patients With Co-Existing Rheumatoid Arthritis

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Nov. 15, 2005--Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of results from its Phase IIIB/IV, 153-patient, four-week, randomized, double-blind, placebo-controlled pilot study evaluating the safety and efficacy of LUNESTA(TM) brand eszopiclone for the treatment of insomnia in patients suffering from rheumatoid arthritis (RA). The results will be presented today at the American College of Rheumatology annual meeting in San Diego.

Back to news